Inhibrx Biosciences stock reports stronger cancer study data

Published on 09/25/2026 at 14:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Inhibrx Biosciences stock was priced at USD 100.40 on September 24, 2026, after Phase 2 data for INBRX-106. The study showed a 48.3 percent response rate.

INBX, US45720L1070, Illustration mit AI erstellt.

Inhibrx Biosciences stock (ISIN US45720L1070) was priced at USD 100.40 on Nasdaq on September 24, 2026, while its 52-week range stood at USD 28.16 to USD 155.29. The latest clinical update showed a 48.3 percent confirmed response rate for INBRX-106 combined with Keytruda, versus 26.5 percent for Keytruda alone.

Phase 2 data sharpen the story

On September 8, 2026, Inhibrx announced interim results from the Phase 2 HexAgon study in treatment-naive, PD-L1-positive head and neck cancer. The study release identified median progression-free survival of 9.6 months for the combination treatment.

The detailed results covered 63 patients evaluable for the primary endpoint, with complete responses in 13.8 percent of patients receiving the combination and 0 percent in the Keytruda-only group. At six months, 72.4 percent of combination-treated patients remained progression-free, compared with 42.8 percent in the control group.

Response gap drives the debate

As Yahoo Finance reported on September 24, 2026, the HPV-positive subgroup produced an 80 percent confirmed response rate with the combination, versus 33.3 percent for Keytruda alone. The subgroup included 10 evaluable combination patients and nine control patients, so the result remains an early clinical signal rather than a mature commercial outcome.

The financial picture is still loss-making. In the second quarter of 2026, Inhibrx posted adjusted earnings per share of negative USD 2.34 against a consensus loss of USD 2.28, a USD 0.06 miss, according to MarketBeat. The company reported USD 133,344,000 in cash and cash equivalents on June 30, 2026.

Price targets remain elevated

MarketBeat reported a Moderate Buy consensus from six brokerages on September 8, 2026, with an average 12-month price target of USD 197.50. HC Wainwright maintained a Buy rating and a USD 245.00 target in a report dated August 24, 2026.

Against the USD 100.40 Nasdaq price on September 24, 2026, the average target is 96.71 percent above the stock price. The gap reflects the market's reliance on clinical execution and regulatory progress rather than current revenue.

INBX stays below its yearly high

INBX traded at USD 100.40 on Nasdaq on September 24, 2026, up USD 0.07, or 0.07 percent, from the prior close of USD 100.33. Trading volume was 285,514 shares, and the market capitalization was USD 1,472,987,074.